Similarly, in BRAF mutation melanoma cells, which acquire resistance to BRAF inhibition, constitutive PD-L1 is elevated through cooperative activation of Jun (a primary target of MAPK signaling) and STAT3 (259). Here, CD274 is linked to melanoma.